JPS588012A - Composition for pig - Google Patents
Composition for pigInfo
- Publication number
- JPS588012A JPS588012A JP56104583A JP10458381A JPS588012A JP S588012 A JPS588012 A JP S588012A JP 56104583 A JP56104583 A JP 56104583A JP 10458381 A JP10458381 A JP 10458381A JP S588012 A JPS588012 A JP S588012A
- Authority
- JP
- Japan
- Prior art keywords
- swine dysentery
- swine
- pig
- feed
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract description 17
- 241000282898 Sus scrofa Species 0.000 claims abstract description 37
- 208000001848 dysentery Diseases 0.000 claims abstract description 29
- 239000002253 acid Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 16
- 239000003242 anti bacterial agent Substances 0.000 abstract description 8
- 229940088710 antibiotic agent Drugs 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 229930184823 lankacidin Natural products 0.000 abstract 2
- FUDDPCATVZFGCZ-UBCGEOKZSA-N (2S)-N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-hydroxypropanamide Chemical compound C[C@H](O)C(=O)N[C@@H]1\C=C(/C)\C=C\[C@@H](O)C\C=C(/C)\C=C\[C@@H](O)C[C@H]2OC(=O)[C@]1(C)C(=O)[C@@H]2C FUDDPCATVZFGCZ-UBCGEOKZSA-N 0.000 abstract 1
- FUDDPCATVZFGCZ-UHFFFAOYSA-N Lankacidinol Natural products CC(O)C(=O)NC1C=C(C)C=CC(O)CC=C(C)C=CC(O)CC2C(C)C(=O)C1(C)C(=O)O2 FUDDPCATVZFGCZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000747254 Streptomyces rochei subsp. volubilis Species 0.000 abstract 1
- LSNBAGMWJRMBEO-VGBMZARNSA-N [(1r,3s,4e,6e,9s,10e,12e,14r,15s,18r)-9-hydroxy-6,12,15,18-tetramethyl-16,19-dioxo-14-(2-oxopropanoylamino)-17-oxabicyclo[13.2.2]nonadeca-4,6,10,12-tetraen-3-yl] acetate Chemical compound C1[C@H](OC(C)=O)\C=C\C(\C)=C\C[C@H](O)\C=C\C(\C)=C\[C@@H](NC(=O)C(C)=O)[C@@]2(C)C(=O)[C@H](C)[C@@H]1OC2=O LSNBAGMWJRMBEO-VGBMZARNSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 241000282887 Suidae Species 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 150000002736 metal compounds Chemical class 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000013312 flour Nutrition 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 125000005313 fatty acid group Chemical group 0.000 description 4
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000027503 bloody stool Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- -1 #Mother Substances 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241001580017 Jana Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000019779 Rapeseed Meal Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000187418 Streptomyces rochei Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000004456 rapeseed meal Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は1赤−の予防治*mtたはilO生麿性向上M
IIL威物に関する。さらに詳しくは、本発明は一般式
〔式中、R戦−0ま九は〈。Hを、VおよびR電それヤ
れ水素または力μボン酸由来OアS/μ基を示す〕で表
わされる化合物を含有してなる豚赤痢の予防治療用を九
は豚の生産性崗上用親戚物である。DETAILED DESCRIPTION OF THE INVENTION The present invention provides 1. Preventive treatment of red-* mt or ilO fertility improvement M
Regarding IIL magistrates. More specifically, the present invention is based on the general formula: H, V and R each represent hydrogen or a S/μ group derived from μ-bonic acid. It is a relative.
豚赤痢は)vダネーマ・バイオディ竜ンテプエ(?rm
ponem hyodys@nt@riae) pcよ
ってひll5Pζ畜れる輸血性下痢を主機とする伝染性
O腸管感染症であって、豚を飼養するほとんどの■でそ
の発生カ認められてお>1 (Ilomaalli、R
ムu4’Lmymy4. W、 IL Th :ムte
atr、 4 th C@31JF、 Xmtmrh
Pigマ*%8oh、Xow*jJBム(197・)〕
、ひとえび発生すると常在化し、清浄化が極めて開離と
なる、このため、と< K)lit飼育の場合、罹患豚
O死亡、発育の低下などによシ経済的に大t11に損失
を招いているのが爽情である。swine dysentery)
Ponem hyodys@nt@riae) It is a contagious O-intestinal infection mainly caused by transfusion-induced diarrhea caused by PC, and its occurrence is recognized in most pigs raised (Ilomaalli, R
Muu4'Lmymy4. W, IL Th: Mute
atr, 4th C@31JF, Xmtmrh
Pigma*%8oh, Xow*jJBmu (197・)]
Once a single shrimp emerges, it becomes permanent, and cleaning becomes extremely difficult.For this reason, in the case of low-quality breeding, there is a large economic loss due to death of affected pigs, reduced growth, etc. It is refreshing to be invited.
との豚赤痢の予防、治療の丸めに、従来、種々の薬剤が
用いられているが、いずれも効力が不十分または安全性
の点で問題があるなど、必ずしも満足し得るものではな
かった。またワクチン等の研究も進められてはいるが十
分な成果が得られておらず、実用化の点で満足のいくも
のは未だ完成されていない。Conventionally, various drugs have been used to prevent and treat swine dysentery, but they have not always been satisfactory, such as insufficient efficacy or safety issues. Although research into vaccines and the like is progressing, sufficient results have not been obtained, and nothing that is satisfactory for practical use has yet to be completed.
本発明者らは、かかる技術的背景の下で鋭意研究をかさ
ねえ結果、化金物(1)が豚赤痢に対し、従来の薬剤で
は達成され得ない顕著な予防および治療効果を奏すると
いう新知見を得、さらに化金物(1)が発育O促進、飼
料O利用性O向上をうながして豚O生産性を高め、畜産
経営上極めて有益であることを見出し丸。The present inventors have carried out intensive research based on this technical background, and as a result have discovered the new finding that chemical compound (1) has remarkable preventive and therapeutic effects against swine dysentery that cannot be achieved with conventional drugs. In addition, it was found that the chemical compound (1) promotes growth O, improves feed O utilization O, increases pig O productivity, and is extremely beneficial for livestock management.
すなわち、本発明は化金物(I)を含有することによ)
豚赤痢Kjtして著効を奏し、しかもきわめて安全性の
高い豚赤痢の予防治療用、ならびに成員促進、飼料効率
の改普による豚の生産性向上O組成物を提供するもので
ある。That is, the present invention is characterized by containing the metal compound (I).
The present invention provides a composition for preventing and treating swine dysentery, which is highly effective against swine dysentery, and is extremely safe, as well as improving pig productivity by promoting population growth and improving feed efficiency.
化金物(I)はフンカシジン(1ankaoidin
)群と総称されるストレプトマイセス・レチェイ・バμ
・ボ〜ビリス(streptom70@a rooh*
i var。Chemical compound (I) is funkaoidin (1ankaoidin).
) group, collectively known as Streptomyces lechei ba μ
・Bobilis (streptom70@a rooh*
i var.
マ01%1bilis )の培養物から分離された抗生
物質(抗生物質?−2636群を構成する>**はそO
鋳導体であって、ヲンカシジンム(R”ニー0.R”:
H、R”: C0CH,) 、フンカシジンc(n”
ニー。Antibiotics (antibiotics? - 2636) isolated from cultures of A.
It is a cast conductor.
H, R”: C0CH,), funkacidin c(n”
knee.
、 R”: H、R’: H) 、 フ/its/N/
−*A (R”:<oHe l”: H、R3: C
ocH,) 、ツンカVシノー!(11:<。!rR1
: H、R3: H)!どの生産菌、製造法および物理
化学的・生物学的性質K)%/mては、例えばザ・ジャ
ーナル拳オプ會アンチビオチタス(J、 Jultlb
iotlos)第24巻1−41頁(111年)に、フ
ン身VジンムS−デ田ピオネ−)(lλ: ■O、R”
: COCl!、C1l、 、 Rs: coaH,)
、 ? y倉Vジ/Ca1−7に?−ト(Rユニ −
o 、 t’: cocyti。, R": H, R': H), F/its/N/
-*A (R”:<oHe l”: H, R3: C
ocH,), Tsunka V Shino! (11:<.!rR1
: H, R3: H)! Which producing bacteria, manufacturing method, and physicochemical/biological properties (K)%/m are known, for example, from The Journal Antibiotics (J, Jultlb).
iotlos) Vol. 24, pages 1-41 (111)
: COCl! , C1l, , Rs: coaH,)
, ? Ykura Vji/Ca1-7? -to (R unit -
o, t': cocyti.
、R”:!り51g18−プw’オ*−)(1’ニー0
゜1”: cocii、C1j、 R’: I ) 、
岡14−rvxヒオ*−) (R”: −0、R”:
H、R3: C0CH,CH,) 、同8.14−シ
ア’に’P −) (R”: −0、R”、 R”:C
0CH,) 、1!Ill 、 14−ジプロピオネー
ト(11:幽0 、 R”、 R”: C0CH,CI
I、 ) 、同8−ベンゾニー) (R1: −0、R
”: C0Ph 、 R”: H) 、岡14−ペン
ゾエート(R1:膣0 、 R”: H、R”: C0
Ph) 。,R":!ri51g18-pw'o*-)(1'knee0
゜1": cocii, C1j, R': I),
Oka 14-rvx Hio *-) (R": -0, R":
H, R3: C0CH,CH,), 8.14-Sia' to 'P-) (R": -0, R", R":C
0CH, ), 1! Ill, 14-dipropionate (11: 0, R", R": C0CH, CI
I, ), 8-benzony) (R1: -0, R
”: C0Ph, R”: H), Oka 14-penzoate (R1: vaginal 0, R”: H, R”: C0
Ph).
同14−フエ二μプロピオネ−)(R1:60,1怠:
H、R”: COCl[、CII、Ph ) 、岡1
4−ニコチネー) (ni: a−Q 、 R”: I
I 、 R”: ニコチン4v)tkEOS造法および
物理化学的・生物学的性質については例えば、ヂ・ジャ
ーナl&/−オプ・アンチビオチタス第26巻647〜
657頁(1973年)K、フン身VシンC14−ホμ
メー)(R1ニー0、 l”: H、II: Co1t
)C)製造法および物理化学的性質については例えば
、特会昭4@−74号公報にそれぞれ記載されている。14-Feniμpropione) (R1:60, 1:
H, R”: COCl[, CII, Ph), Oka1
4-nicotine) (ni: a-Q, R”: I
I, R”: Nicotine 4v)tkEOS production method and physicochemical/biological properties, for example, in Journa l&/- Op Antibiotitas, Vol. 26, 647-
657 pages (1973) K, Hunmi V Shin C14-Hoμ
(R1 knee 0, l”: H, II: Co1t
) C) The production method and physicochemical properties are described, for example, in Tokukai Publication No. 4@-74.
なシフンtI¥Vンム、C,ツンカVジノールム、ラン
カシシノーμの生産菌であるストレプトマイセス・ツチ
ェイ・バ〃・ボμビリスは、財団法人発酵研究所および
アメリカン・タイプ・力μチユアー・コレクションに微
生物受託番号 XFO12507およびATCC212
59としてそれぞれ寄託されている。Streptomyces tscheiba bilis, which is the producing bacterium of NasifuntI¥Vunmu, C, Tsunka V Ginorum, and Lankashisinomu, has been donated to the Fermentation Research Institute and the American Type Culture Collection. Microbial accession numbers XFO12507 and ATCC212
59, respectively.
上記し九一般式(I)KおけるRa>よびRsとしての
カルボン酸由来OアV〜基は低il腫訪酸a1&(例、
ホμミL、アセチμ、プロピオニ声、グチリμ、インブ
チリル、バレ9!、ヘキyすμなど好ましくは炭素数1
〜Tのもの)中芳書族力μボン酸残基(@、ペンシイμ
表どのアマーμカμボン酸残基、ニコチノイμなどのへ
デー芳香族カルボン酸残基)が好ましく、この低級脂肪
酸残基はその末端がフェニル基によ)置換されていても
よい(例、フエニμア篭チβ、フエ二μデ撃ビオニμ謙
と)。The carboxylic acid-derived OaV~ group as Ra> and Rs in the above-mentioned nine general formulas (I)
Homi L, Acechi μ, Propioni Voice, Guchiri μ, Inbutiril, Barre 9! , hexaμ, etc. preferably have 1 carbon number
~ T) in the aromatic force μ bonic acid residue (@, pence μ
Preferred are aromatic carboxylic acid residues such as amer μ carboxylic acid residues and nicotinoid μ μ carboxylic acid residues, and this lower fatty acid residue may be substituted at its terminal with a phenyl group (e.g., Fueni μa Kagochi β, Fueni μ de Gekibioni μ Ken and).
本発明に用いられる化金物(1)のうちでもと) bケ
R” 、 R”カソレソtt水素を九はCx −Ca
OII肪酸残基であるものが好ましい、なかでもツンカ
Vジ/A 、 ’)ン25/l):/C、9ン力syf
ンc14−プ!ビオネート、阿8−アセテート、−3−
デ田ビオネート、フンカ¥Vノーμム、フン力vfノー
ルまえはこれらの混合物を用いるのがよい。Of the metal compounds (1) used in the present invention, bkeR", R"casolesottt hydrogen is Cx-Ca
Those that are OII fatty acid residues are preferred, especially those that are OII fatty acid residues, especially those that are OII fatty acid residues.
c14-p! bionate, a8-acetate, -3-
It is better to use a mixture of these: deta bionate, hunka\vnorm, hunriki vfnormae.
と〉わけ、ランカVジンムを九は(およヒ)ヲンカVジ
ンCが有利に用いられる。In particular, Ranka V Jinmu 9 (Oyohi) Wonka V Jin C can be used advantageously.
本発明の豚用!i威物は、化合物(1)で表わされる化
合物の1種を含有していてもよく、数種の化金物(1)
を同時に含有していてもよい。さらに上記ストレプトマ
イセス・ロチェイ・パμ・ボ〃ビリスの醗酵培地をその
まま、その乾燥物またはその抽出物として用いることが
できる。For pigs according to the invention! The chemical substance may contain one type of compound represented by compound (1), and may contain several types of chemical substances (1).
may be contained at the same time. Further, the above-mentioned fermentation medium of Streptomyces rochei pa.
本発明の豚赤痢予防治療用を九は豚の生産性生産性組上
物は、化金物(1)を固状i九は液状の希釈剤で希釈し
、を九は希釈せずに、あるーは被覆等によ)安定化し、
例えば散剤、粉剤、111粒剤、錠剤、液剤、ペースト
剤、カブ七μ剤、注射剤などとするか、あるいは飼料、
飲水などに1直接まえは−たん希釈剤中に分散させ丸も
のを添加するととKよシ製造される。希釈剤としては、
自体生理学的に無害なものであればいかなるものでもよ
く、飼料もしくは飼料の一成分とな〉うるものがさらに
望ましい。固体担体としては、例えば大麦粉、小麦粉、
裸麦粉、トウモロコy粉、大豆粉、大豆粕、菜種粕、モ
ミガフ、米メカ、脱脂メカ、カンFit粉、バレイシミ
粉、トウ7粕、でん粉、乳糖、庶糖、ブドウ糖、果糖、
#母、廃酵母。The product for the prevention and treatment of swine dysentery of the present invention is prepared by diluting the chemical compound (1) with a solid diluent, and without diluting it. (by coating etc.),
For example, powder, powder, 111 granule, tablet, liquid, paste, turnip tablet, injection, etc., or feed,
It is produced by dispersing it in a diluent and adding whole pieces directly to drinking water. As a diluent,
Any material may be used as long as it is physiologically harmless in itself, and it is more desirable that it can be used as feed or a component of feed. Solid carriers include barley flour, wheat flour,
Naked wheat flour, corn flour, soybean flour, soybean meal, rapeseed meal, fir gaff, rice mecha, skimmed mecha, KanFit flour, barley stain flour, Tou 7 lees, starch, lactose, sucrose, glucose, fructose,
#Mother, waste yeast.
魚粉、り〜り、酸性白土、クレイなどが挙げられ、液状
担体としては、例えば水、生理的食塩水、生理学的に無
害な有機溶媒などがあげられる。その飽適宜O補助剤、
例えば乳化剤1分散剤、懸濁剤、湿潤剤、濃縮剤、ゲμ
化剤、可溶化剤を適当量添加しても差支えない。さらに
防腐剤 *曹剤。Examples of the carrier include fish meal, lily, acid clay, and clay. Examples of liquid carriers include water, physiological saline, and physiologically harmless organic solvents. O adjuvant as appropriate for its saturation,
For example, emulsifier 1 dispersant, suspending agent, wetting agent, concentration agent, gel μ
There is no problem in adding an appropriate amount of a curing agent or a solubilizing agent. Furthermore, preservatives *Soda.
抗生物質、酵素剤、乳酸lll1剤を配合してもよく、
これらO組成物にビタミン、1ネヲp、ア稟ノ酸などを
配合してもよい。Antibiotics, enzyme agents, and lactic acid agents may be combined.
These O compositions may also be blended with vitamins, 1, 1, 1, 1, 2, 1, 2, 3, 3, 3, 3, 3, 4, 5, 6, 7, 8, 1, 2, 3, 3, 3, 3, 4, 4, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , .
本発明の豚赤痢予防治療用!えは豚O生魔性内上用組虞
物の投与量は豚O年令)症状、投与方法などKよって適
宜選択しうるが、例えば豚赤痢O予防の間約には化合物
(1)を約0005〜25IIlk47旦投与するのが
好ましく、ζO場場合化金物(1)0濃度が約1〜S
@ Opp鳳と)わけ2〜200PPMKなるように飼
料中に添加して摂食させるのがよい。また豚赤痢の治療
O目的には化合物(1)として約L 1〜25ダ/k
g/8投与するのが好ましく、この場合は約2〜500
ppm とシわけ約2.5〜200ppm となるよう
に飼料中に添加するのがよい。一方、豚の生産性向上の
目的には化合物(1)として約0.025〜l0QF/
kg/日投与するのが好ましく、この場合は約0.5〜
200ppm と)わけ約1〜10100pp となる
ように飼料中に添加するのがよい。For prevention and treatment of swine dysentery according to the present invention! The dosage of the composition for internal use can be selected depending on the pig's symptoms (age), administration method, etc., but for example, during the prevention of swine dysentery, compound (1) should be administered to the pig. It is preferable to administer once 0005-25IIlk47, and when the ζO concentration is about 1-S
@ Opp Otori) It is best to add it to the feed so that the amount is 2 to 200 PPMK. In addition, for the purpose of treating swine dysentery, compound (1) is used at approximately 1 to 25 da/k.
Preferably, the dose is about 2-500 g/8.
It is preferable to add it to the feed at a concentration of about 2.5 to 200 ppm. On the other hand, for the purpose of improving pig productivity, approximately 0.025 to 10QF/
It is preferable to administer about 0.5 kg/day.
It is preferable to add it to the feed in an amount of about 1 to 10,100 ppm (200 ppm).
化金物(1)の動物に対する毒性は極めて低く、九とえ
はマウスを用い九急性毒性試験では、経口投与によるL
D、0がランカFspyC,W414−プロピオネート
およびフン方Vジンムと%1亀OOOダ/kg以上で、
腹腔内投与によるLD、。がツン*vyンhではII、
000〜10,000q/k1.、フンカシジンC14
−プロピオネートでは10.00011F/kg以上、
ツンカVジンCでは4.5001F/−であった。The toxicity of chemical compound (1) to animals is extremely low, and in an acute toxicity test using mice, it was found that oral administration of L
D, 0 is Ranka FspyC, W414-propionate and Funka V Jim and more than %1 turtle OOO da/kg,
LD, by intraperitoneal administration. ga tsun*vynh II,
000-10,000q/k1. , Funkacidin C14
-10.00011F/kg or more for propionate,
In Tunka V Jin C, it was 4.5001F/-.
これは製造・流過に当って人への安全性が高いことを示
すばかシでなく、対象動物への許春景が広い丸め、九と
えば飼料に混合して投与する場合、相当程度の混合の不
均一性があって4対象動物O安全性を保証することが出
来ることを示している。This does not mean that it is highly safe for humans during production and distribution, but that Xu Chunjing to target animals is widely rounded. It has been shown that there is heterogeneity in the number of animals tested and that safety can be guaranteed.
次に実験例および実施例により本発明をさらに詳しく説
明するが、これらが本発明の籠■を制限する%Oではな
いことはいう壕でもない。Next, the present invention will be explained in more detail with reference to experimental examples and examples, but it is not to be said that these do not limit the %O of the present invention.
実験例/
豚赤痢の起因菌であるトVポネーマ・ハイオデイセンテ
リエに対する試験管内抗菌力試験を柏崎らOrトレボネ
ーマ ハイオデイセンテリエの薬剤感受性測定法」(第
82回日本獣医学会講演要W101頁:昭和51年)K
準じで測定し丸、結果は第1褒に示すとお〉、ヲンカF
vンCは強−抗菌活性を示したが、比較に供し九他O抗
生物質は−ずれも無効で6つ九。Experimental example / In vitro antibacterial activity test against Trebonema hyodei senteriae, the causative bacterium of swine dysentery. : 1978) K
Measure according to the same method, and the result will be shown in the first prize〉, Wonka F
VnC showed strong antibacterial activity, but nine other antibiotics were used for comparison, all of which were ineffective.
第1表
(1) 11株: いずれも我国の豚赤痢罹息豚0粘
血便から分離され* Trepome+aa hyod
ygemteria*に属する菌株
(2)抗菌力測定法: Agar DilutiOl
l Method(寒天平板希釈法)
(3)接種菌量: 10’CFIJ/m厘液1白壺耳
(4)培養条件: Ga5Pak(BBL)法、31
゜2日培費
実験例λ
実験例1と同様の方法で化金物(1)0代表例について
試験管内抗菌力試験を実施した。七〇@71開昭58−
8012 (4)
果は142表に示すとお)で、若干最小発育阻止濃度に
差はあるがいずれもトレボネーマハイオディセンテリエ
に顕著な抗菌活性を示し丸。Table 1 (1) 11 strains: All of them were isolated from the mucus-blood stool of pigs with swine dysentery in Japan* Trepome + aa hyod
Bacterial strain belonging to Ygemteria* (2) Antibacterial activity measurement method: Agar DilutiOl
l Method (agar plate dilution method) (3) Amount of inoculated bacteria: 10'CFIJ/m solution 1 white pot ear (4) Culture conditions: Ga5Pak (BBL) method, 31
゜2-day culture experiment example λ An in vitro antibacterial activity test was carried out on a representative example of chemical compound (1) 0 in the same manner as in experiment example 1. 70@71 Kaisho 58-
8012 (4) The fruit is shown in Table 142), and although there is a slight difference in the minimum inhibitory concentration, all of them show remarkable antibacterial activity against Trebonema hyodysenteriae.
注)実験条件は実験例/、(第1表)KMじ実験例3
実験例/と同様の方法で化金物(1)Kついて試験管内
抗厘力試験を寮施し友、七〇@果はmS表に示すとお9
で、いずれもトレボ車−マ・へイオデイ七ンテプエに顕
著な抗菌活性を示しえ。Note) Experimental conditions are Experimental Example/, (Table 1) KM Experimental Example 3 In vitro resistance test was conducted on chemical compound (1) K in the same manner as in Experimental Example/. 9 shown in mS table
All of them showed remarkable antibacterial activity in Trebocarma.
第3表
賓験例ベ
マウスを用いた実験的豚赤痢感染におけ為フンカVジン
ム、フンカVジンC,ヲンカS/シンCs−アセテート
、フン倉シジンCl4−プロピオネート、フンiIVシ
ノーμムおよびフン方Vシノーfi10抗豚赤痢効果試
験を寮施し丸。Table 3: Experimental Examples of Experimental Swine Dysentery Infection Using Vemous Mouse: Funka V Jinmu, Funka V Jin C, Wonka S/Sin Cs-Acetate, Funka Shigin Cl4-Propionate, Funka IIV Synome μ and Funka V Shino fi10 anti-swine dysentery efficacy test was conducted in the dormitory.
タトエハインフエタVMン アンド インムニテイ第2
5巻757−764)頁(1975年)。Tatoehainhueta VM'n and Inmunity 2nd
5, pp. 757-764) (1975).
アメダカン ジャーナμ オプ ベテツナターヅサーチ
第41巻1225〜1226頁(1980年)およびベ
テリナリー レコード第107巻527ん529頁(1
980年)などに記載されているジエンズらと同様のマ
ウスの寮験的豚赤痢惑染モデμを用い九。すなわち5%
馬脱線血液加)デデテイケイス ソイアW−(Tryp
ticaa・soyagar; BBLjl)平板上に
嫌気培養し丸Treponem hyodysente
ri’i’!’jjF離株を培地ごと磨砕し、トリデテ
イケイス ソイ グロス(’!’ryptiaaae
soy brotJ B B Llll )で2倍希釈
し丸感染材料をマウスの胃内KM種しえ。薬剤は5xア
ヲビアゴム溶液に懸濁し感染1日後から4日後まで強制
経口投与した。感染T目後に盲腸部の病変を観察すると
共に盲腸を内春物とも磨砕し?repem@m hyo
dys@nt@ria* 11数を測定しえ。Amedakan Jana μ op Vetetsu Nataz Search Vol. 41 pp. 1225-1226 (1980) and Veterinary Record Vol. 107 pp. 527-529 (1980)
Using a mouse experimental swine dysentery infection model μ similar to that described by Ziens et al. i.e. 5%
Tryp
ticaa soyagar; BBLjl) was cultured anaerobically on a plate.
ri'i'! 'jjF isolates were ground together with the medium, and the
The infected material was diluted 2 times with soy brot (JBB Lllll) and inoculated into the stomach of mice. The drug was suspended in a 5x gum avia solution and administered orally by force from 1 day to 4 days after infection. After the infection, the lesions in the cecum were observed and the cecum was ground up with an inner surface. repem@m hyo
dys@nt@ria* Measure 11 numbers.
結果は114表に要約されるとお)華剤家与瀞ではいず
れもすぐれた有効性を示し丸。The results are summarized in Table 114) All of the products in Hanazyakuya Yodo showed excellent efficacy.
実験例よ
実験的感染条件下でヲンカVジンCの抗豚赤痢効果試験
を突施し丸。すなわち、6遍令のランドレース種子豚1
6頭(1群4頭)を供試し、抗菌性物質を含まない自家
配舎O子豚用人工乳BK試験薬剤を100 ppHlの
濃度に&るよう添加混合して、子豚にそれぞれ自由摂食
させえ、豚への感染は、あらかじめ5X馬血液加寒天平
板上K>いて嫌気培養しえTrepeneukyody
smteria* 79/ム株を培地ごと磨砕し、5X
ムチン加リン酸緩衝液と混和したものをapr豚の胃内
Kl[JI投与することによシ行った。ついで典型的な
豚赤痢の発症を認め良縁より、その結腸内容物および粘
膜を採取し、5Xムチン加リン酸緩衝液で2倍に希釈し
九40を最終的な感染材料とし、試験豚がT遍令の時に
その100dずつを胃内に直接注入(えだし、感染前の
24時閲絶食)、感染させ、感染!I21日関飼育した
。結果は第5表に要約されるとお〉、!9ドマイシンは
無効であったがツンカyジンCは豚赤痢に*してすぐれ
え有効性を示して−る。Experimental example: We conducted an anti-swine dysentery efficacy test of Wonka V Jin C under experimental infection conditions. Namely, 6-year-old Landrace sow 1
Six pigs (4 pigs per group) were tested, and a test drug for home-housed piglet formula BK containing no antibacterial substances was added and mixed to a concentration of 100 ppHl, and each piglet was given ad libitum. To infect pigs, infect pigs by culturing them anaerobically on a 5X horse blood agar plate in advance.
smteria* 79/mu strain was ground together with the medium, and 5X
This was done by administering Kl [JI] mixed with mucin-containing phosphate buffer to APR pigs. Next, the colon contents and mucous membranes of the pigs were collected from a good friend when the onset of typical swine dysentery was observed, diluted 2 times with 5X mucin-containing phosphate buffer, and 940 was used as the final infection material. At the time of pilgrimage, 100 d of each was injected directly into the stomach (eating, fasting 24 hours before infection), causing infection! I21 Hinoseki was bred. The results are summarized in Table 5. Although 9domycin was ineffective, Tsunkayjin C has shown excellent efficacy against swine dysentery.
次頁へ琥〈
注)成績は感染から剖検までの21日間の11[当シ平
均。Go to next page. Note: Results are 11 [our average] for the 21 days from infection to autopsy.
横列アμファベット異符号間に有意差あ)(P<0.0
5)。There is a significant difference between row alphabets with opposite signs) (P<0.0
5).
九とえばaとbfilK有意差あシ
bとab間では有意差なし
実験例&
ランカS/ジンCについて、飼料中濃度を1100pp
から更に下げ、抗豚赤痢剤として一般的に繁用すれて−
る力μパドツクスとの対比も含めて、実験例よと同様の
方法で試験を実施し丸。結果は第6表に要約されるとお
〉で、ランカVyンCは飼育成績の上からも力μパドツ
クスよ)優れ九抗豚赤痢剤であることが判明し友。For example, there is no significant difference between a and bfilK. Experimental example & Ranka S/Jin C, the concentration in the feed is 1100pp
It has since been further lowered and is now commonly used as an anti-swine dysentery agent.
The test was conducted in the same manner as in the experimental example, including the comparison with the force μ pads. The results are summarized in Table 6.Lanca VynC was found to be an excellent anti-swine dysentery agent in terms of breeding results.
第6表 注)成績は感染〜剖検までの21日関01頭当シ平均。Table 6 Note) Results are averages for 21 days from infection to necropsy per animal.
横列アμファベット^符号11に有意差あ)(P<0.
05)
丸とえばaboと(IIIKは有意116)1abcと
aa閏には有意差なし
実験例71
実験例tと同様にして、フンカシジンムおよびフンカシ
ジンCl4−プロピオネート IOppm投与時の抗豚
赤病効果試験を実施した。結果は第7表に要約されると
お)で、フンカシジンムおよ 5びフンカンジンC1
4−プロピオネートとも豚赤痢に対して明らかな有効性
を示しだ。There is a significant difference in the row alphabet ^ sign 11) (P<0.
05) For example, there is no significant difference between abo, (IIIK is significant 116) 1abc and aa. Experimental Example 71 In the same manner as Experimental Example t, an anti-swine red blight effect test was conducted when administering Juncasidinmu and Juncasidin Cl4-propionate IOppm. carried out. The results are summarized in Table 7).
Both 4-propionate showed clear efficacy against swine dysentery.
第7表 注)成績は感染〜剖検までの21日間の1頭当シ平均。Table 7 Note: Results are average per animal for 21 days from infection to necropsy.
横列アルファベット異符号間に有意差あ夛(P<0.0
5)
実験例1
本実験例では豚赤痢発症と同時に投薬を行う、いわゆる
治療的投薬の条件で実施した。感染方法は実験例よと同
様で試験には感染後同一日(6日目)K発症した5頭を
用い、発症と同時にランカシジンC5Q Pp!l添加
飼料を給与した。結果は第8表に示すとおシ、金側とも
投与翌日には粘血下痢便は止まって軟便から正常側とな
)、2日目には糞便中の菌数も検出成算(l 0tCF
U/g)以下となった。発症後15日目(体薬9日目)
K実施し九剖検所見では大腸に病変は全く認められずW
4m検出されなかつ丸。There is a significant difference between the horizontal alphabets with different signs (P<0.0
5) Experimental Example 1 This experimental example was carried out under the conditions of so-called therapeutic medication, in which medication was administered at the same time as the onset of swine dysentery. The infection method was the same as in the experimental example, and five dogs that developed symptoms on the same day (6th day) after infection were used for the test, and lancasidin C5Q Pp! was administered at the same time as the onset of symptoms. 1 supplementary feed was given. The results are shown in Table 8. On the day after administration, the mucus and bloody stools stopped and the stools changed from soft to normal. On the second day, the number of bacteria in the stools was also detected (10tCF).
U/g) or less. 15th day after onset (9th day of physical medication)
An autopsy was performed and no lesions were found in the large intestine.
4m not detected.
第8表
注)便性状は4段階に分けて判定(0,正常;■、軟便
;■、下痢便茶0.粘血下痢便)。Table 8 Note: Stool properties were divided into four grades (0, normal; ■, soft stool; ■, diarrhea brown; 0, mucus bloody stool).
1数はlog /gで示し、(−)は検出It算(l
o”c rU7g )以下を示す。1 The number is shown in log/g, and (-) is the detection It calculation (l
o”cr rU7g) The following is shown.
傘はフンカシジンC50ppm添加飼料の給与日を示す
。The umbrella indicates the feeding date of the feed supplemented with 50 ppm of Funkacidin C.
実験例り
実験例よと同様にして豚赤痢治療的投薬の条件下におけ
るフンカシジン類の治療効果を試験した。EXPERIMENTAL EXAMPLE The therapeutic effect of funcasidins under the conditions of therapeutic administration for swine dysentery was tested in the same manner as in the experimental example.
賽験方援核実験例8に従い便性状によシ効果を判定した
。結果は第9表に示すとおシ、フンカVジンム、フンカ
シジンCおよび同14−グロビオネートはseppm投
与によ〉治療効果を有することが判明した。The effect on stool properties was determined according to Experimental Example 8. The results are shown in Table 9. It was found that Junka V-Zim, Junkacidin C, and Junkacidin 14-globionate had therapeutic effects when administered with seppm.
(以下余白)
第9表
注)硬性状は4段階に分けて判定(○、正常;■、軟便
;■、下痢便;O1粘血下痢便)。(Margins below) Table 9 Note) Hardness was determined in four stages (○, normal; ■, soft stool; ■, diarrheal stool; O1 mucus-bloody diarrhea stool).
中薬物添加飼料の給与口を示す。Indicates the feeding port for medium-drug-added feed.
上記実験例/〜9の結果から明らかなように1化合物(
I)は豚赤痢の予防治療剤として極めて優れ九効果を発
揮し、類似抗生物質またはすでに市販され繁用されてい
る抗原赤痢剤に比べて優位性を示し、畜産経営上、極め
て有効である。As is clear from the results of Experimental Examples/~9 above, one compound (
I) is extremely effective as a prophylactic and therapeutic agent for swine dysentery, and is superior to similar antibiotics or antigenic dysentery agents that are already commercially available and in frequent use, and is extremely effective in livestock management.
実験例10
豚赤痢の介在しない吠況下でO豚の発育に対する化合物
(1)の効果を試験し丸。すなわち、1力号令のランド
レース種子豚5腹401[を供試−し、1群8頭(雄4
.雌4)からなる51Fを設置し友。Experimental Example 10 The effect of compound (1) on the growth of O pigs was tested under barking conditions without the involvement of swine dysentery. In other words, 401 litters of 5 Landrace pigs of 1-power age were tested, with 8 pigs per group (4 males).
.. 51F consisting of 4 females was installed and friends.
フンカシジン、Cの飼料への添加濃度はO(財11)、
1,2.5.5および10pp鳳とし、開始から3力月
令までは抗菌剤無添加の人工乳11に、 4力月令から
6力月令(終了)までは豚産肉能力検定用飼料(同じく
抗菌剤無添加)に文れぞれ添加混合して、5Il月関に
わ木って番IIFK連−給与し丸。The concentration of funkacidin and C added to feed is O (Goods 11),
1, 2, 5, 5, and 10pp. From the start to the 3rd month of age, antibacterial-free artificial milk 11 is used, and from the 4th to 6th month of age (end), it is used for pig meat production ability test. We added and mixed each of these ingredients to the feed (also without the addition of antibacterial agents) and fed them to the IIFK Ren.
結果は第1031に要約されるとおシ、フンカシジンC
の添加濃度の増加にほぼ比例して豚の発育が促進され、
飼料の利用性が向上し、化合物(■)は通常の飼育条件
下でも豚の生産性向上に有用である。The results are summarized in No. 1031.
The growth of pigs is promoted in approximately proportion to the increase in the added concentration of
Feed availability is improved and compound (■) is useful for improving pig productivity even under normal breeding conditions.
注)成績は1頭当りの平均。Note) Results are averages per animal.
横列アルファベット異符号間に有意差(P〈◎、05)
あす。Significant difference between horizontal alphabets with different signs (P〈◎, 05)
tomorrow.
たとえばaとbには有意差あ〉 abとa、abとbには有意差なし。For example, there is a significant difference between a and b. There is no significant difference between ab and a, and ab and b.
実験例//
35日令のフントレース種子iis腹48頭を供試し、
1群8頭(塩4.雌4)からなる6Ilを設第11表
注)成績は1頭当夛の平均。Experimental example // 48 35-day-old Huntrace seed IIS bellies were tested;
6Il was established, consisting of 8 animals per group (4 salts, 4 females). Table 11 (Note) Performance is the average of 1 group.
横列アルファベット異符号間に有意差(P<0.05)
あり。Significant difference between horizontal alphabets with different signs (P<0.05)
can be.
実施例1
例えば下記の基礎飼料またはその原料の一部に任意濃度
の化合物(1)を配合することによ漫、本発明の豚赤痢
予防治療用シよび豚の生産性向上用組成物ないしそのプ
レミックスを製造することができる。Example 1 The composition for preventing and treating swine dysentery and the composition for improving swine productivity of the present invention can be prepared, for example, by incorporating compound (1) at an arbitrary concentration into a part of the following basic feed or its raw materials. Premixes can be produced.
基礎飼料組成(%)
&)+kg中V、A250万IU、V、Ds50万IU
、 V、E O,75g 、71 ・硝酸I411g、
Y、に15g、VJ、0.25g、V、kl”F、パン
トテン酸力〜Vウム3.5g、ニコチン酸アミド7.5
g、塩化コリア50g、鉄50g、鋼5g、亜鉛25g
、マンガン15g、コバルト0.25g、ヨード0.1
gを含有b) A混合物、B混合物およびC混合物を
9. 15:0.+5:0.lの割合で混合したものを
用いた。Basal feed composition (%) &)+kg V, A 2.5 million IU, V, Ds 500,000 IU
, V, E O, 75g, 71 ・Nitric acid I 411g,
Y, 15g, VJ, 0.25g, V, kl”F, pantothenic acid power ~ Vum 3.5g, nicotinic acid amide 7.5
g, coria chloride 50g, iron 50g, steel 5g, zinc 25g
, manganese 15g, cobalt 0.25g, iodine 0.1
b) A mixture, B mixture and C mixture containing 9. 15:0. +5:0. A mixture of 1 ml and 1 ml was used.
ム混合物:マンガン5%、鉄5%、銅1%。Mixture: 5% manganese, 5% iron, 1% copper.
亜鉛6%、ヨー素0.IXを含有
B混合物:1g中V、A1万IU、V、D、20001
Uを含有
C混合物:1kg中IBI・硝酸塩1 g、 V、’B
m7g、V、に0.5g+ニコチン酸アミド6g。Zinc 6%, iodine 0. B mixture containing IX: V, A 10,000 IU, V, D, 20,001 in 1 g
C mixture containing U: IBI/nitrate 1 g in 1 kg, V, 'B
m7g, V, 0.5g + nicotinic acid amide 6g.
Claims (1)
れぞれ水素まえは倉μボン酸由来のアVfi/基を示す
〕で表わされる化金物を含有してなゐ豚赤痢の予防治療
用1!えは豚の生産性崗上用親威物。[Claims] General formula ′ [In the formula, V stands for 10. , V and 171m respectively represent a hydrogen group and a Vfi/group derived from Kurabonic acid] 1 for the prevention and treatment of swine dysentery. Eha is a great product for pig productivity.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56104583A JPS588012A (en) | 1981-07-03 | 1981-07-03 | Composition for pig |
| US06/324,635 US4425356A (en) | 1980-11-29 | 1981-11-24 | Lankacidin derivatives used in swine husbandry |
| NL8105334A NL192722C (en) | 1980-11-29 | 1981-11-25 | A method of preparing a pharmaceutical preparation. |
| FR8122180A FR2494964A1 (en) | 1980-11-29 | 1981-11-26 | IMPROVED TREATMENT IN PORK BREEDING AND COMPOSITION USED FOR THIS TREATMENT |
| IT68548/81A IT1146721B (en) | 1980-11-29 | 1981-11-27 | COMPOSITION FOR PROPHYLAXIS AND CARE OF PIG DYSENTERY OR FOR INCREASING PIG GROWTH |
| GB8135932A GB2088715B (en) | 1980-11-29 | 1981-11-27 | Improvements in swine husbandry and composition therefor |
| DK527581A DK171070B1 (en) | 1980-11-29 | 1981-11-27 | Feeds for increasing the growth of pigs, premix for their preparation and methods for obtaining them |
| BE0/206677A BE891275A (en) | 1980-11-29 | 1981-11-27 | IMPROVEMENTS IN PIG FARMING AND COMPOSITIONS USED THEREFOR |
| CH7629/81A CH649467A5 (en) | 1980-11-29 | 1981-11-27 | COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF PIG DYSENTERIES OR INCREASING PIG PRODUCTIVITY. |
| CA000391067A CA1195930A (en) | 1980-11-29 | 1981-11-27 | Swine husbandry and composition therefor |
| DE19813147311 DE3147311A1 (en) | 1980-11-29 | 1981-11-28 | IMPROVEMENT IN PIG FARMING AND THEREFORE PARTICULAR COMPOSITION |
| MX9202938A MX9202938A (en) | 1981-07-03 | 1992-06-17 | COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF PIG LIVESTOCK DISENTERIA AND TO INCREASE ITS PRODUCTIVITY. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56104583A JPS588012A (en) | 1981-07-03 | 1981-07-03 | Composition for pig |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS588012A true JPS588012A (en) | 1983-01-18 |
| JPS637525B2 JPS637525B2 (en) | 1988-02-17 |
Family
ID=14384451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56104583A Granted JPS588012A (en) | 1980-11-29 | 1981-07-03 | Composition for pig |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS588012A (en) |
| MX (1) | MX9202938A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62240687A (en) * | 1985-12-05 | 1987-10-21 | Takeda Chem Ind Ltd | Lankacidin derivative and production thereof |
| JPH0646319A (en) * | 1992-03-18 | 1994-02-18 | Sanyo Electric Co Ltd | Moving vector detection circuit |
-
1981
- 1981-07-03 JP JP56104583A patent/JPS588012A/en active Granted
-
1992
- 1992-06-17 MX MX9202938A patent/MX9202938A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62240687A (en) * | 1985-12-05 | 1987-10-21 | Takeda Chem Ind Ltd | Lankacidin derivative and production thereof |
| JPH0646319A (en) * | 1992-03-18 | 1994-02-18 | Sanyo Electric Co Ltd | Moving vector detection circuit |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS637525B2 (en) | 1988-02-17 |
| MX9202938A (en) | 1992-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533593T2 (en) | PREPARATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDER CONTAINING ARABINOGALACTAN AND POLYPHENOLS OF LARIX. | |
| Varel et al. | Enumeration and activity of cellulolytic bacteria from gestating swine fed various levels of dietary fiber | |
| DE69828188T2 (en) | FEED PRODUCT | |
| DE3873402T2 (en) | ANTIMICROBIC PREPARATIONS. | |
| KR101893735B1 (en) | Pharmaceutical copositions for animal of previntion of intestinal disorder the same method | |
| CN114304413B (en) | Composite containing acidifying agent and preparation method thereof | |
| JP5192108B2 (en) | Composition for inhibiting methanogenesis and composition for feed for ruminants | |
| US4223040A (en) | Lauric acid for the prevention and treatment of mycobacterial diseases | |
| CN113749187A (en) | Production method of glucose oxidase feed additive containing catalase | |
| JPS588012A (en) | Composition for pig | |
| Horn Jr et al. | The effect of antibiotics upon the digestion of feed nutrients by yearling steers, with bacteriological data | |
| DE2015334A1 (en) | Composition for the treatment of acidosis in ruminants | |
| CH646059A5 (en) | ANTIBIOTIC COMPOSITIONS CONTAINING A MACROLIDE AND AN AMINOHETEROSIDE. | |
| DE2928074A1 (en) | PREPARATION FOR THE PROPHYLAXIS AND THERAPY OF THE PIG DYSENTERIA | |
| US4425356A (en) | Lankacidin derivatives used in swine husbandry | |
| CN120555246B (en) | Composite microbial agent for improving disease resistance of livestock and poultry and preparation method thereof | |
| KR100464847B1 (en) | Clostridium butyricum having preventive and therapeutic effects on hepatopathy, and liver supporting agents, foods and feeds each containing the culture medium thereof | |
| Hedde et al. | Virginiamycin activity and safety in ruminants | |
| EP0063238B1 (en) | An efficiency-improving agent for feed and a preventive and treating agent for coccidiosis | |
| EP3838347B1 (en) | Evernimicin for treating diseases like necrotic enteritis | |
| KR20210031340A (en) | A weight-increasing microbial additive for livestock use that has activated according to the composition of the ratio of Firmicutes, Bacteroides, Actinobacteria and Proteobacteria in digestive tract. | |
| Roine et al. | The mode of action of aureomycin in the guinea-pig | |
| Gwatkin et al. | Attempts to Infect Swine with S. suipestifer | |
| JP2000270784A (en) | Feed for cattle and poultry | |
| CN121370756A (en) | Water-soluble diclazuril solution and preparation method thereof |